Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/31875| Title: | Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter? | Austin Authors: | Pereira-Salgado, Amanda;Anton, Angelyn;Franchini, Fanny;Mahar, Robert K;Kwan, Edmond M;Wong, Shirley;Shapiro, Julia;Weickhardt, Andrew J ;Azad, Arun A;Spain, Lavinia;Gunjur, Ashray ;Torres, Javier;Parente, Phillip;Parnis, Francis;Goh, Jeffrey;Steer, Christopher;Brown, Stephen;Gibbs, Peter;Tran, Ben;IJzerman, Maarten | Affiliation: | Centre for Cancer Research and Centre for Health Policy, Faculty of Medicine, Dentistry and Health Sciences, the University of Melbourne, Melbourne, Australia. Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia. Western Health, Melbourne, Australia. Alfred Health, Melbourne, Australia. Olivia Newton-John Cancer Wellness and Research Centre Peter MacCallum Cancer Centre, Melbourne, Australia. Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia. Goulburn Valley Health, Shepparton, Australia. Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia. Adelaide Cancer Centre, Adelaide, Australia. Royal Brisbane and Women's Hospital, Brisbane, Australia. Border Medical Oncology, Albury Wodonga Regional Cancer Centre, Albury, Australia. Ballarat Health Services, Ballarat, Australia. Department of Personalised Medicine, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. |
Issue Date: | 2023 | Date: | 2022 | Publication information: | Expert Review of Pharmacoeconomics & Outcomes Research 2023; 23(2) | Abstract: | Health economic outcomes of real-world treatment sequencing of androgen receptor-targeted agents (ARTA) and docetaxel (DOC) remain unclear. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/31875 | DOI: | 10.1080/14737167.2023.2161048 | ORCID: | 0000-0002-8459-7961 |
Journal: | Expert Review of Pharmacoeconomics & Outcomes Research | Start page: | 1 | End page: | 9 | PubMed URL: | 36541133 | ISSN: | 1744-8379 | Type: | Journal Article | Subjects: | Health economics metastatic castration-resistant prostate cancer prostate cancer time-to-treatment failure treatment costs treatment sequences |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.